{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:31:28Z","timestamp":1780342288208,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.jneuroim.2014.07.016","type":"journal-article","created":{"date-parts":[[2014,7,30]],"date-time":"2014-07-30T08:32:26Z","timestamp":1406709146000},"page":"108-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Dermatomyositis as a presentation of neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"278","author":[{"given":"David","family":"Delman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianming","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Zedek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Jewells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Chahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silva","family":"Markovic-Plese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2014.07.016_bb0005","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1007\/s00296-011-2323-y","article-title":"Anti-MDA5 antibody is associated with A\/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis","volume":"32","author":"Chen","year":"2012","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jneuroim.2014.07.016_bb0010","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.4049\/jimmunol.1102705","article-title":"Ifih1 gene dose effect reveals MDA5-mediated chronic type I IFN gene signature, viral resistance, and accelerated autoimmunity","volume":"188","author":"Crampton","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2014.07.016_bb0015","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2014.07.016_bb0020","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2014.07.016_bb0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/PL00007850","article-title":"Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies","volume":"249","author":"Hengstman","year":"2002","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2014.07.016_bb0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2014.07.016_bb0035","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2014.07.016_bb0040","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1471-2474-11-223","article-title":"Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis","volume":"11","author":"Kang","year":"2010","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.jneuroim.2014.07.016_bb0045","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2014.07.016_bb9000","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet."},{"key":"10.1016\/j.jneuroim.2014.07.016_bb0050","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/01.bor.0000245721.02512.77","article-title":"Cancer and myositis: new insights into an old association","volume":"18","author":"Levine","year":"2006","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jneuroim.2014.07.016_bb9005","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1600-0560.2007.00848.x","article-title":"Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus","volume":"35","author":"McNiff","year":"2008","journal-title":"J. Cut. Path."},{"key":"10.1016\/j.jneuroim.2014.07.016_bb9010","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11926-012-0246-6","article-title":"Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment","volume":"14","author":"Mimori","year":"2012","journal-title":"Curr Rheum Rep."},{"key":"10.1016\/j.jneuroim.2014.07.016_bb0055","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/00207454.2013.854208","article-title":"Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?","volume":"124","author":"Ontaneda","year":"2014","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.jneuroim.2014.07.016_bb0060","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archneur.65.5.629","article-title":"Aquaporin-4 autoantibodies in a paraneoplastic context","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2014.07.016_bb9015","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","article-title":"Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease","volume":"23","author":"Sato","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jneuroim.2014.07.016_bb0065","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/BOR.0b013e32833f1075","article-title":"Malignancy and myositis: novel autoantibodies and new insights","volume":"22","author":"Selva-O'Callaghan","year":"2010","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jneuroim.2014.07.016_bb0070","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2014.07.016_bb0075","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","article-title":"Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis","volume":"46","author":"Yamasaki","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.jneuroim.2014.07.016_bb9020","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jaad.2010.08.004","article-title":"Enhanced skin expression of melanoma differentiation-associated gene 5 (MDA5) in dermatomyositis and related autoimmune diseases","volume":"64","author":"Zahn","year":"2011","journal-title":"J Am Acad Derm."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572814002318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572814002318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:24:27Z","timestamp":1759047867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572814002318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":20,"alternative-id":["S0165572814002318"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2014.07.016","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatomyositis as a presentation of neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2014.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}